Key result
Coronary artery bypass grafting significantly improved 10-year survival compared to medical therapy in patients with triple-vessel disease (92.2% vs 64.2%), but showed similar outcomes in double-vessel disease with good left ventricular function.
Why the study?
Does medical therapy compared to CABG improve long-term survival in patients with multivessel coronary artery disease?
Cohort (n=1,185)
No
Does medical therapy compared to CABG improve long-term survival in patients with multivessel coronary artery disease?
CABG provides a significant long-term survival benefit over medical therapy in patients with triple-vessel disease or multivessel disease with reduced left ventricular function, whereas medical therapy is comparable to CABG for double-vessel disease with preserved LV function.
The long-term results of medical therapy and coronary artery bypass grafting (CABG) were compared in patients with multivessel disease. All patients were confirmed to have > or = 75% luminal narrowing of major coronary arteries by coronary arteriogram. When multivessel disease was stratified into double- and triple- vessel disease, the outcomes varied. In triple-vessel disease, the outcome with CABG was good, but the outcome was unfavorable in those employing medical therapy, particularly in patients with decreased left ventricular (LV) function. In patients with double-vessel disease with good LV function, the long-term results with medical therapy were just as favorable as those with CABG. However, double-vessel disease complicated by reduced LV function (ejection faction < or = 40%) had a clearly less favorable outcome when treated with medical therapy than with CABG. Thus, it is important for patients with multivessel disease to undergo revascularization if indicated, to improve their prognosis. On the other hand, the incidence of cardiac events arising from vein graft occlusions tended to increase in CABG patients after 5 years or more following surgery.
No takes yet. Share an insight, caveat, or question.
Nishiyama et al. (1995) conducted a cohort in Multivessel Coronary Artery Disease (n=1,185). Coronary Artery Bypass Grafting (CABG) vs. Medical therapy was evaluated on 10-year survival (triple-vessel disease). Coronary artery bypass grafting significantly improved 10-year survival compared to medical therapy in patients with triple-vessel disease (92.2% vs 64.2%), but showed similar outcomes in double-vessel disease with good left ventricular function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: